热门资讯> 正文
YS Bizerma报告900万个结果
2024-04-20 05:35
- YS Biopharma press release (NASDAQ:YS): 9M Net loss for the first nine months of fiscal 2024 was US$35.6 million
- Revenue of $61.9M.
More on YS Biopharma
- YS Biopharma Co., Ltd. (YS) Q3 2024 Earnings Call Transcript
- YS Biopharma announces full repayment of $40M loan facility
- YS Biopharma announces $40M private placement
- Seeking Alpha’s Quant Rating on YS Biopharma
- Historical earnings data for YS Biopharma
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。